Fundeni Clinical Institute

Running trials

• Not yet recruiting

  Euvolemia-Based Assessment of Pulmonary Hypertension in Stable Hemodialysis Patients

  NCT07676786· Source

• Recruiting

  Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)

  NCT07575347· Source

• Recruiting

  Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral Pathologies

  NCT07332234· Source

• Recruiting

  #AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.

  NCT06900829· Source

• Recruiting

  A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

  NCT07202884· Phase 3· Source

• Recruiting

  Master Framework For Relapse or Refractory Acute Myeloid Leukemia

  NCT06459024· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Source

• Active, not recruiting

  A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

  NCT05827016· Phase 3· Source

• Recruiting

  Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis

  NCT05207358· Phase 4· Source

• Active, not recruiting

  A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

  NCT05152147· Phase 3· Source

• Active, not recruiting

  A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT05160584· Source

• Active, not recruiting

  Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease

  NCT05043103· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease3 recruiting
• High blood pressure2 recruiting
• Lupus (SLE)2 recruiting
• Acute myeloid leukemia1 recruiting
• Childhood cancers1 recruiting
• Coronary artery disease1 recruiting
• Fabry disease1 recruiting
• HIV1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Pathological and Clinical Features of Patients Treated With ATZ+BEV in Romania

  NCT06903663· Source

• Completed

  Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)

  NCT06499948· Phase 4· Source

• Active, not recruiting

  A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

  NCT05888493· Phase 3· Source

• Completed

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· Phase 4· Source

• Completed

  A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

  NCT04567615· Phase 2· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Source